New Delhi, March 18 Mankind Pharma announced on Wednesday that it has acquired the Rivotril brand from Roche for the Indian market, gaining exclusive rights to manufacture, market, and distribute the product across the country.
Rivotril is the original brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions.
This acquisition builds on the company's growing focus on chronic therapies, where it has steadily expanded its presence through new launches, licensing partnerships, and portfolio additions across key therapeutic areas.
"This acquisition aligns with our strategic focus on strengthening our presence in chronic and specialty therapies. Going forward, we see strong opportunities to build on this platform through potential product extensions, addressing the evolving needs of patients and physicians in the CNS therapy area," Atish Majumdar, Senior President, Sales & Marketing, Mankind Pharma Specialty Business, said in a statement.
Chronic therapies now account for a growing share of Mankind's overall business as it continues to expand its specialty segments and deepen engagement with specialists and key opinion leaders.
Furthermore, the addition of Rivotril, a well-known brand among specialists, will strengthen its CNS portfolio and expand treatment options for patients managing neurological conditions.